Global HIV Drugs Market 2015-2019
HIV is a type of retrovirus that causes infection in human beings. AIDS is a life-threatening disease caused by this virus. In this disease certain white blood cells (lymphocytes) are destroyed, resulting in the loss of the body's ability to protect itself against infections. The major route of transmission of HIV infection is unprotected sex, contaminated needle, breast milk, and infected blood. HIV attacks the body's white blood cells, specifically a subset called CD4 or helper T cells. The anti-retroviral therapy is used to treat the patient and help the immune system fight the infection. This is mainly used to keep the level of the HIV low in the body.
Technavio's analysts forecast the global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection.
Based on the class of drugs, the market is segmented as follows:
Technavio Announces the Publication of its Research Report – Global HIV Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global HIV Drugs Market: Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, and Merck.
Other Prominent Vendors in the market are: AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Emcure, F. Hoffmann-La Roche, Hetero Drugs, Mylan, Pfizer, Shionogi, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from Technavio’s team said: “Strategic alliances formed between companies, in terms of licensing and collaboration, is a key market trend that is helping co-development and commercialization of drugs in different regions.”
According to the report, unmet medical needs in the market present significant growth opportunities for vendors.
Further, the report states that adverse effects such as hepatotoxicity, hyperglycemia, hyperlipidemia, lactic acidosis, lipodystrophy, osteonecrosis, osteopenia, osteoporosis, and skin rash presents a significant challenge to this market.
Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Emcure, F. Hoffmann-La Roche, Hetero Drugs, Mylan, Pfizer, Shionogi, Teva Pharmaceutical Industries.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook